The phase 1 clinical trials evaluated escalating doses of CB-839 in patients with advanced solid tumors among the patients with triple-negative breast cancer, RCC, mesothelioma, NSCLC, fumarate hydratase (FH)-deficient tumors, succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) or non-GIST tumors, cMyc-mutated tumors, and isocitrate dehydrogenase-1 (IDH1)- or IDH2-mutant tumors in combination with standard of care chemotherapy. Here, MYC is linked to gastrointestinal stromal tumor.